Details

Autor(en) / Beteiligte

• HILDEBRANDT, Bert
• RAU, Beate
• DORKEN, Bernd
• RIESS, Hanno
• LÖFFEL, Jürgen
• WUST, Peter
• NICOLAOU, Annett
• GELLERMANN, Johanna
• LE COUTRE, Philipp
• NEUHAUS, Peter
• FELIX, Roland
• WERNECKE, Klaus-Dieter

Titel

Adjuvant chemotherapy with folinic acid and 5-fluorouracil in patients with locally advanced rectal cancer previously treated by preoperative radiochemotherapy and curative tumor resection

Ist Teil von

• International journal of colorectal disease, 2006-09, Vol.21 (6), p.582-589

Ort / Verlag

Heidelberg: Springer

Erscheinungsjahr

2006

Link zum Volltext

Quelle

SpringerLink Journals

Beschreibungen/Notizen

• The role of postoperative adjuvant chemotherapy in patients with rectal cancer pretreated by preoperative radiochemotherapy (RCT) and curative surgery is still poorly investigated. We pooled data from both arms of a phase III trial in which patients with locally advanced (T3/4) rectal cancer were randomized to preoperative RCT alone or combined with pelvic radio-frequency hyperthermia. After surgery, R0-resected patients were scheduled to adjuvant chemotherapy with four monthly courses of 50 mg folinic acid (FA) and gradually escalated 5-fluorouracil (5-FU, 350-500 mg/m2, days 1-5). Reasons preventing initiation of chemotherapy and treatment-related toxicities were evaluated. Patients' characteristics and survival parameters were compared between the treated and untreated patient groups. Out of 93 patients, 73 (79%) started adjuvant chemotherapy, whereas 19 (21%) did not, mostly due to perioperative complications and refusal. Chemotherapy-related toxicities were mild to moderate in most cases, but--together with protracted postoperative complications--prevented the intended dose escalation of 5-FU in 71% of patients. Distant-failure-free (p=0.03) and overall survival (p=0.03) were improved in the chemotherapy group, although there was a negative selection of patients with unfavourable characteristics into the untreated patient group. Adjuvant chemotherapy using FA and 5-FU can be safely applied to the majority of patients with rectal cancer pretreated by RCT and surgery. Survival data are not suitable to allow far-reaching conclusions, but are in line with suggestions of a favourable effect of adjuvant chemotherapy in these patients.